Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HighLiGHts weekly lonapegsomatropin versus daily somatropin in growth hormone-sufficient short stature disorders
2025-523079-44-00Phase 3Authorised
- Sponsor
- Ascendis Pharma
- Start
- Apr 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of lonapegsomatropin in Turner syndrome (TS), SHOX haploinsufficiency, Small for gestational age (SGA) and 1 more (2 arms), sponsored by Ascendis Pharma. Primary endpoint: Annualized height velocity at Week 52. Planned start Apr 2026; status: authorised.
02
Drugs
lonapegsomatropin
03
Conditions
Turner syndrome (TS)SHOX haploinsufficiencySmall for gestational age (SGA)Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on 2025-523079-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523079-44-00.